(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/114205 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/26* (2006.01)
A61K 9/10 (2006.01) *A61K 47/38* (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:
PCT/US2022/052704

(22) International Filing Date:
13 December 2022 (13.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/289,965 15 December 2021 (15.12.2021) US

(71) Applicants: **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; 6701 Rockledge Drive, Suite 700, MSC 7788, Bethesda, Maryland 20892-7788 (US). **SRI INTERNATIONAL** [US/US]; 333 Ravenswood Avenue, Menlo Park, California 94025 (US).

(72) Inventors: **LEE, Min**; NIH/NICHD, 6710B Rockledge Drive, Bethesda, Maryland 20892 (US). **BLITHE, Diana**; NIH/NICHD, 6710B Rockledge Drive, Bethesda, Maryland 20892 (US). **FANG, Jia-Hwa**; SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025 (US). **RUIZ, Eduardo**; SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025 (US). **CHEN, Ken**; SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025 (US).

(74) Agent: **SCHWARTZ, Johanna P.** et al.; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, Oregon 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(54) Title: LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO

LNGB Inhibition of Ovulation – Subcutaneous vs. Intramuscular Injection (40 mg dose)




FIG. 6

(57) Abstract: Disclosed herein are formulation embodiments comprising levonorgestrel butanoate ("LNGB") particles having particle sizes that facilitate administering a higher concentration of LNGB at lower volumes. The disclosed formulation embodiments exhibit long-lasting contraceptive effects and can be administered subcutaneously, which lends to their utility in acting as self-administrable contraceptive formulations that do not result in side effects associated with other contraceptive agents.

WO 2023/114205 A1

[Continued on next page]

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*